Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-20093 for injection in metastatic castration-resistant prostate cancer and other advanced solid tumors
CTR20232508Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in prostate cancer (PCa), sponsored by Hansoh Pharmaceutical Group. Started Jan 2024; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20232508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232508.